Your session is about to expire
← Back to Search
abaloparatide for Myelodysplastic Syndrome
Study Summary
This trial is testing a new treatment for Myelodysplastic Syndromes (MDS) that combines abaloparatide with bevacizumab. The goal is to find out if it is safe and effective, and if it improves patients' quality of life.
- Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 511 Patients • NCT04064411Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has abaloparatide been tested in any other research trials previously?
"At this time, there are 361 ongoing trials related to abaloparatide, with 89 of them in Phase 3. The majority of these studies originate from Taibei, Taiwan; however there is research being conducted at 17027 different locations worldwide."
Is recruitment still ongoing for this medical experiment?
"According to data hosted on clinicaltrials.gov,this medical study has completed its recruitment process and is not presently accepting new patients; the original posting was February 14th 2019 and the last update occurred August 10th 2022. However, there are 1969 other clinical trials actively recruiting individuals at this time."
How many people are currently participating in this clinical trial?
"Unfortunately, the recruitment process for this trial concluded on August 10th 2022. If you are searching for alternative clinical trials, 1608 studies involving patients with leukemia, myelomonocytic or chronic conditions and 361 studies dealing with abaloparatide are currently open to participants."
Is abaloparatide a risk-free option for individuals?
"Abaloparatide has been reviewed by our team at Power and deemed to have a safety score of 1 due to the lack of evidence supporting its efficacy in Phase 1 trials."
To what types of ailments is abaloparatide traditionally allocated?
"Abaloparatide is typically used to battle cancer, including recurrent platinum sensitive primary peritoneal cancer, stage IV epithelial ovarian cancer post-surgical resection, and locally advanced nonsquamous non-small cell lung cancer."
Share this study with friends
Copy Link
Messenger